Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Drucker

Showing results (31-40 of 313) with videos related to

Pageof 32
Sort By:
Diabetologia|February 7, 2021
Transforming type 1 diabetes: the next wave of innovationDaniel J Drucker
The Diabetes Educator|March 24, 2006
Incretin-based therapies: a clinical need filled by unique metabolic effectsDaniel J Drucker
The New England Journal of Medicine|September 19, 2024
Discovery of GLP-1-Based Drugs for the Treatment of ObesityDaniel J Drucker
Cell Metabolism|April 5, 2018
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Daniel J Drucker
Diabetes|August 24, 2018
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular ComplicationsDaniel J Drucker
Gastroenterology|February 8, 2002
Biological actions and therapeutic potential of the glucagon-like peptidesDaniel J Drucker
Cell Metabolism|March 7, 2006
The biology of incretin hormonesDaniel J Drucker
Cell Metabolism|June 28, 2016
The Cardiovascular Biology of Glucagon-like Peptide-1Daniel J Drucker
Annual Review of Physiology|October 29, 2013
Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2Daniel J Drucker, Bernardo Yusta
Nature Reviews. Endocrinology|December 12, 2022
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1Rola Hammoud, Daniel J Drucker
Pageof 32

Showing results (31-40 of 313) with videos related to

Sort By:
Pageof 32
Diabetologia|February 7, 2021
Transforming type 1 diabetes: the next wave of innovationDaniel J Drucker
The Diabetes Educator|March 24, 2006
Incretin-based therapies: a clinical need filled by unique metabolic effectsDaniel J Drucker
The New England Journal of Medicine|September 19, 2024
Discovery of GLP-1-Based Drugs for the Treatment of ObesityDaniel J Drucker
Cell Metabolism|April 5, 2018
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Daniel J Drucker
Diabetes|August 24, 2018
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular ComplicationsDaniel J Drucker
Gastroenterology|February 8, 2002
Biological actions and therapeutic potential of the glucagon-like peptidesDaniel J Drucker
Cell Metabolism|March 7, 2006
The biology of incretin hormonesDaniel J Drucker
Cell Metabolism|June 28, 2016
The Cardiovascular Biology of Glucagon-like Peptide-1Daniel J Drucker
Annual Review of Physiology|October 29, 2013
Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2Daniel J Drucker, Bernardo Yusta
Nature Reviews. Endocrinology|December 12, 2022
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1Rola Hammoud, Daniel J Drucker
Pageof 32